Split Intein-based Selection for Modified Peptide Binders to SARS-CoV-2 Spike Protein
Exclusively Licensed
Invention type: Technology
/
Case number: #22502
Disclosed herein, in some embodiments, non-naturally occurring proteins (e.g., non-naturally occurring modified proteins) that may be useful in the treatment of bacterial and viral infections, including SARS-CoV-2 infection, host cells comprising the same, and methods of treating bacterial and viral infections including SARS-CoV-2 infection.
Researchers
Christopher Voigt
/
Andrew King
/
Emerson Glassey
Departments: Department of Biological Engineering
Technology Areas: Biotechnology: Synthetic Biology / Drug Discovery and Research Tools: Genomics & Proteomics / Therapeutics: Proteins & Antibodies
Impact Areas: Healthy Living
-
split intein-based selection for peptide binders
United States of America | Published application
Sign up for technology updates
Sign up now to receive the latest updates on cutting-edge technologies and innovations.